Definitive Chemoradiotherapy of Limited-disease Small Cell Lung Cancer: Retrospective Analysis of New Predictive Factors Affecting the Treatment Results

Komatsu, Tetsuya; Oizumi, Yukio; Kunieda, Etsuo; Tamai, Yoshifumi; Akiba, Takeshi; Kogawa, Asuka

doi:10.1016/j.ijrobp.2010.07.1243

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, some studies suggest that the ratio of radiation dose to tumor diameter is related to the prognosis of limited-stage SCLC. Still, there is a lack of data on radiation dose in this study ( Komatsu et al, 2010 ).…”

Section: Discussionmentioning

confidence: 86%

High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer

Huang

Pan

Liu

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Purpose: eHSP90α is closely related to tumor progression and prognosis. This study aimed to investigate the significance of eHSP90α in the response evaluation and prediction of small cell lung cancer.Methods: We analyzed the relationship between eHSP90α expression and clinicopathological features in 105 patients with small cell lung cancer. Univariate and multivariate analyses were used to determine the association of parameters and ratios with response assessment, progression-free survival (PFS), and overall survival (OS).Results: In SCLC patients, eHSP90α and NSE were positively correlated. The cutoff values of eHSP90α in OS, PFS, and response evaluation were 61.2 ng/ml, 48.7 ng/ml, and 48.7 ng/ml, respectively. eHSP90α could better predict OS, PFS, and response evaluation (AUC OS 0.791, PFS 0.662, 0.685). Radiotherapy and eHSP90α were independent variables for effective chemotherapy through univariate and multivariate analysis. In contrast, radiotherapy, eHSP90α, NSE, and M stage were independent variables for OS. eHSP90α, and M stage were independent variables for PFS. Kaplan-Meier analysis showed that higher eHSP90α expression predicted poorer OS and earlier progression in patients.Conclusions: This study aims to provide new evidence for the efficacy response and prognostic assessment of SCLC. eHSP90α may be a better biomarker for SCLC.

show abstract

Section: Discussionmentioning

confidence: 86%

High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer

Huang

Pan

Liu

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Patients who received early TRT typically presented with good hematopoietic function and could tolerate concurrent chemoradiotherapy, and it is widely known that concurrent chemoradiotherapy is superior to a sequential regimen in the treatment of SCLC . More importantly, patients in the early TRT group had short durations between the start of chemotherapy and radiotherapy administration, which has been demonstrated to affect survival in several previous studies . Murray et al .…”

Section: Discussionmentioning

confidence: 99%

“…3,7 More importantly, patients in the early TRT group had short durations between the start of chemotherapy and radiotherapy administration, which has been demonstrated to affect survival in several previous studies. 5,6,14,15 Murray et al reported that the prolongation of SER (time between the start of any treatment and the end of radiation therapy) resulted in more frequent brain metastasis, 6 and a study from Japan yielded similar results, causing the author to speculate that SER affects survival because of the probability of distant metastasis, but not local control. 15 This tendency was also demonstrated in our study; specifically, the DM rates in the late TRT group were significantly higher than those in the early TRT group, and the LRR rates were not significantly different between the two groups.…”

Section: Discussionmentioning

confidence: 99%

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

et al. 2015

View full text Add to dashboard Cite

BackgroundTo investigate whether the response to induction chemotherapy (IC) would impact the timing of thoracic radiotherapy (TRT) in limited-stage small-cell lung cancer (LS-SCLC).MethodsA total of 146 patients with LS-SCLC who had received two to six cycles of IC followed by TRT from January 2009 to December 2011 at our hospital were included in this study. Patients were divided into two groups based on the time TRT was administered: early TRT (administered after 2–3 cycles of chemotherapy) or late TRT (administered after 4–6 cycles). Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method. Multivariate Cox regression analysis was performed to evaluate the independent factors affecting survival.ResultsThe median OS for patients who received early TRT and late TRT was 29.0 and 19.9 months, respectively, (P = 0.018) and the median PFS was 18.5 and 13.8 months, respectively (P = 0.049). In patients who achieved complete remission (CR) or partial remission (PR) after two to three cycles of IC, the median OS was 36.1 and 22.5 months in the early and late TRT subgroups, respectively (P = 0.009); the corresponding median PFS was 20.2 and 13.8 months, respectively (P = 0.038). In the patients who did not achieve CR or PR, no statistic difference was found in OS or PFS between the two subgroups.ConclusionPatients who received early TRT had more favorable outcomes than those who received late TRT. Patients who achieved CR or PR after two to three cycles of IC obtained more benefit from early TRT.

show abstract

Definitive Chemoradiotherapy of Limited-disease Small Cell Lung Cancer: Retrospective Analysis of New Predictive Factors Affecting the Treatment Results

Cited by 2 publications

References 9 publications

High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer

High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

Contact Info

Product

Resources

About